Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Metadata
Title
FDA: Evidentiary standards for drug development and approval
Author
Russell Katz
Publication date
01-07-2004
Publisher
Springer-Verlag
Published in
Neurotherapeutics / Issue 3/2004
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1602/neurorx.1.3.307

Other articles of this Issue 3/2004

Neurotherapeutics 3/2004 Go to the issue

OriginalPaper

Evidence-based ethics for neurology and psychiatry research

OriginalPaper

Funding evidence: The National Institute of Neurological Disorders and Stroke Clinical Trials Program

OriginalPaper

Policy-relevant research: When does it matter?

OriginalPaper

Evidence from clinical trials: Can we do better?

Editorial

Evidence-based neurotherapeutics: A spectrum of evidence

OriginalPaper

Evidence from biomarkers and surrogate endpoints